Assessing an innovative treatment of PCOS in young patients
As the most frequent cause of anovulatory subfertility, polycystic ovary syndrome (PCOS) affects a significant percentage of adolescents and young women worldwide. In a landscape that lacks effective therapies, pilot studies have led to the development of a novel medication focused on the reversion of the PCOS phenotype without side effects through a single tablet called SPIOMET. The EU-funded SPIOMET4HEALTH project aims at evaluating this innovative approach focusing on the additive effects of SPIOMET's components. The project aspires to provide the first large-scale evidence on the psychosocial benefits of the tested treatments and to contribute to solid decision-making about PCOS across European healthcare systems.
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action
07121 Palma De Mallorca
08970 Sant Joan Despi
12006 Castellón De La Plana